Personnel Information

写真a

FUJIKI Tamami


Job title

Assistant Professor
To the head of this page.▲

Campus Career 【 display / non-display 】

  • 2014.04
    -
    2015.03
    Tokyo Medical and Dental University， (Old Organization)Medical Hospital， Hospital Departments， Department of Internal Medicine， Nephrology， Resident
  • 2017.04
    -
    2021.03
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Medical and Dental Sciences， Systemic Organ Regulation， Nephrology， Graduate Student
  • 2021.04
    -
    2021.09
    Tokyo Medical and Dental University， (Old Organization)Medical Hospital， Hospital Departments， Department of Internal Medicine， Nephrology， Project Assistant Professor
  • 2021.10
    -
    2022.03
    Tokyo Medical and Dental University， Tokyo Medical and Dental University， Division of Clinical Medicine， Department of Internal Medicine， Nephrology， Project Assistant Professor
  • 2022.04
    -
    2022.06
    Tokyo Medical and Dental University， Tokyo Medical and Dental University， Division of Clinical Medicine， Department of Internal Medicine， Nephrology， Assistant Professor
  • 2022.07
    -
    2023.03
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Medical and Dental Sciences， Systemic Organ Regulation， Nephrology， Assistant Professor
  • 2023.04
    -
    2024.08
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Endowed Departments， Department of Nephrology and Regional Health(ibaraki)， Assistant Professor
  • 2024.09
    -
    Now
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Endowed Departments， Department of Nephrology and Regional Health(ibaraki)， Assistant Professor

▼display all

To the head of this page.▲
 

Published Papers & Misc 【 display / non-display 】

  1. Tamami Fujiki, Fumiaki Ando, Kana Murakami, Kiyoshi Isobe, Takayasu Mori, Koichiro Susa, Naohiro Nomura, Eisei Sohara, Tatemitsu Rai, Shinichi Uchida. Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation. Sci Rep. 2019.06; 9 (1): 9245. ( PubMed, DOI )

  2. Fujiki Tamami, Hirasawa Suguru, Watanabe Seishi, Iwamoto Shunsuke, Ando Ryoichi. 極めて重篤なTAFRO症候群に対してステロイドなしのトシリズマブ治療が奏効した1例(Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome) CEN Case Reports. 2017.05; 6 (1): 105-110. ( ichushi )

To the head of this page.▲

Conference Activities & Talks 【 display / non-display 】

  1. Fujiki T, Ando F, Mandai S, Isobe K, Susa K, Mori T, Nomura N, Sohara E, Rai T, Uchida S.. Tolvaptan and Bardoxolone Methyl Synergistically Activate the Nrf2/HO-1 pathway.. ASN Kidney Week 2019 2019.11.08

  2. Tamami Fujiki, Fumiaki Ando, Kiyoshi Isobe, Takayasu Mori, Koichiro Susa, Naohiro Nomura, Eisei Sohara, Tatemitsu Rai, Shinichi Uchida. Tolvaptan activates Nrf2/HO-1 pathway through PERK phosphorylation. The 52nd Annual Meeting of American Society of Nephrology, Kidney Week 2018 2018.10.26 San Diego

To the head of this page.▲